Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease – Immune complex
Reexamination Certificate
2001-06-15
2003-09-30
Nolan, Patrick J. (Department: 1644)
Chemistry: analytical and immunological testing
For preexisting immune complex or auto-immune disease
Immune complex
C436S508000, C435S007100, C435S007210
Reexamination Certificate
active
06627458
ABSTRACT:
Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
BACKGROUND OF THE INVENTION
Atypical “antineutrophil cytoplasmic antibodies” (ANCA) are present in patients with ulcerative colitis (UC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) ANCA represent a family of heterogenous autoantibodies directed against constituents of neutrophilic granulocytes. These autoantibodies have become valuable seromarkers for the diagnostic and therapeutic management of patients with systemic vasculitides such as Wegner granulomatosis and microscopic polyangiitis, in which they recognize well defined cytoplasmic antigens such as proteinase 3 and myeloperoxidase. Two well established ANCA staining patterns can be distinguished on ethanol-fixed neutrophils: a difuse cytoplasmic fluorescence pattern (c-ANCA) and a fine homogeneous labeling of the perinuclear cytoplasm (p-ANCA).
Autoantibodies that are similar to p-ANCA in patients with systemic vasculitides are detected in individuals with chronic inflammatory bowel diseases (IBD) such as ulcerative colitis or autoimmune liver disorders such as primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Contrary to systemic vasculitides, the role of ANCA in these disorders is not clear. Various cytoplasmic proteins such as bactericidal/permeability increasing protein, catalase, cathepsin G, enolase, or lactoferrin have been proposed as putative target antigens of ANCA in these disorders, but reactivity to these proteins has only been detected in less than thirty five percent of cases. The predominant target antigen of ANCA in IBD and autoimmune liver disorders has not been identified. Since their target antigens are unknown, p-ANCA in patients with IBD or autoimmune liver disorders are generally referred to as atypical p-ANCA.
ANCA are generally defined as autoantibodies directed against cytoplasmic antigens localized in the azurophil and specific granules of neutrophils (Woude et al., 1985; Savige et al, 1999). Using double-labeling immunofluorescence microscopy, it was shown that this definition holds true only for C-ANCA and classic p-ANCA in systemic vasculitides, but not for ANCA in individuals with IBD and autoimmune liver disease (Billing et al, 1995; Terjung et al., 1998). ANCA in those disorders do not react with cytoplasmic structures (Billing et al, 1995; Terjung et al., 1998). Their fluorescence pattern examined by indirect immunofluorescence microscopy is characterized by a broad inhomogeneous labeling of the nuclear periphery along with multiple intranuclear fluorescent foci. By means of immuno electron microscopy, it has been shown that this focal intranuclear fluorescence likely corresponds to invaginations of the nuclear envelope (Fricker et al., 1997; Terjung et al., 1998). These labeling characteristics of atypical p-ANCA in IBD and autoimmune liver disorders strongly suggest that a nuclear antigen is the target (possibly the term ANCA (antineutrophil cytoplasmic antibody) is a misnomer, and the term ANNA (antineutrophil nuclear antibody) is more appropriate).
Previously, it has been suggested that histone H1, particularly its isoform H1-3, is a candidate antigen recognized by atypical p-ANCA in patients with UC (Targan et al., 1996; Cohavy et al., 1997,; and Cohavy et al. 1998). Furthermore, reactivity to this nuclear antigen in 42 percent of sera from T-cell receptor alpha-deficient mice that developed UC like syndrome and whose sera contained ANCA has also been reported (Mizoguchi et al., 1997). In addition, eighty nine percent of sampled patients with AIH had antibodies that recognized high mobility group (HMG ½) non-histone chromosomal proteins (Sobajima et al., 1997). Although neither histone H1 nor HMG ½ proteins are neutrophil specific, it has been hypothesized that certain epitopes of these nuclear proteins are only immunoaccessible in neutrophils and therefore might represent target proteins of atypical p-ANCA (Targan et al., 1996; Cohavy et al., 1997,; and Cohavy et al. 1998). However, these studies do not exclude the possibility that atypical p-ANCA predominantly recognize another myeloid specific nuclear protein.
Therefore, a need arises to characterize the nuclear antigen recognized by atypical p-ANCA. The main impetus behind this need is that molecular identification of the target antigen will result in the development of highly specific, sensitive, and reproducible assays for the detection of atypical p-ANCA in the routine clinical laboratory setting. These assays will have diagnostic use for patients with IBD, in particular UC and autoimmune liver disorders, in particular PSC ans AIH.
SUMMARY OF THE INVENTION
The present invention is directed to the molecular characterization of the nuclear antigen recognized by atypical p-antineutrophil cytoplasmic antibodies (p-ANCA), thus permitting better diagnosis of patients with inflammatory bowel diseases such as ulcerative colitis (UC), and autoimmune liver diseases such as primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH). Molecular characterization of the target antigen comprises preparing cytoplasmic and nuclear extracts of human neutrophils, human HL-60 and murine 32D myeloid cells. Proteins are resolved by 1 and 2 dimensional gel electrophoresis and reactive proteins are detected by immunoblotting with sera from individuals, making certain to have both normal and disease controls. Atypical p-ANCA can further be affinity purified against the reactive protein and investigated for their immunofluorescence pattern using confocal microscopy. The antigen that atypical p-ANCA can recognize is isolated or partially purified and used to detect the presence of atypical p-antineutrophil cytoplasmic antibodies so as to diagnose patients with inflammatory bowel diseases such as ulcerative colitis (UC), and autoimmune liver disease such as primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH).
REFERENCES:
Terjung et al., Clinical and Experimental Immunology, vol. 120 S1-p 53, May 2000.*
Terjung et al., Gastroenterology vol. 116, No. 4 part 2, p. A831, Apr. 1999.*
Billing, P., Tahir, S., Calfin, B., Gagne, G., Cobb, L., Targan, S., Vidrich, A. (1995). Nuclear localization of the antigen detected by ulcerative colitis associated perinuclear antineutrophil cytoplasmic antibodies.. Am J Pathol, 147:979-987. (Exhibit 1).
Cohavy, O., Eggena, M.P., Parseghian, M., Hamkalo, B., Targan, S.R., Gordon, L.K., Braun, J., Histone H1. (1997). A candidate pANCA antigen in ulcerative colitis (abstr). Gastroenterology 112:A951. (Exhibit 2).
Cohavy, O., Tayebali, A.B., Phu, P.K., Eggena, M.P., Parseghian, M.H., Hamkalo, B.A., Targan, S., Braun, J. (1998). Characterization of the pANCA cor epitope in the histone H1 C terminus (abstr). Gastroenterology 114:A953. (Exhibit 3).
Courvalin, J.C., Lassoued, K., Bartnik, E., Blobel, G., Wozniak, R.W. (1990). The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 86:279-285. (Exhibit 4).
Courvalin, J.C., Lassoued, K., Worman, H.J., Blobel, G. (1990). Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary billiary cirrhosis. J Exp Med 172:961-967. (Exhibit 5).
Courvalin, J.C., Worman, H. J., (1997). Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 17: 79-90. (Exhibit 6).
Eggena, M., Targan, S.R., Iwanczyk, L., Vidrich, A., Gordon, L.K., Braun, J. (1996). Phage display cloning and characterization of an immunogentic marker (perinuclear a
Terjung Birgit
Worman Howard J.
Cooper & Dunham LLP
Nolan Patrick J.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Nuclear envelope protein recognized by atypical p-ANCA in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nuclear envelope protein recognized by atypical p-ANCA in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclear envelope protein recognized by atypical p-ANCA in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3099276